SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
暂无分享,去创建一个
Marc P. Bonaca | Deepak L. Bhatt | Lawrence A Leiter | M. Sabatine | Darren K Mcguire | S. Wiviott | I. Raz | John P H Wilding | Thomas A. Zelniker | Ofri Mosenzon | Eri Toda Kato | Remo H M Furtado | K. Im | Erica L. Goodrich | Avivit Cahn
[1] Declare–Timi Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .
[2] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.
[3] K. Mahaffey,et al. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function , 2018, Circulation.
[4] E. Braunwald,et al. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. , 2018, Journal of the American College of Cardiology.
[5] S. Garg,et al. Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. , 2018, Diabetes technology & therapeutics.
[6] Sonal Singh,et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes , 2018, JAMA internal medicine.
[7] K. Mahaffey,et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. , 2018, The lancet. Diabetes & endocrinology.
[8] S. Solomon,et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus , 2018, Circulation.
[9] T. Chowdhury,et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. , 2018, Primary care diabetes.
[10] B. Zinman,et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease , 2018, Circulation.
[11] K. Mahaffey,et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events , 2017, Circulation.
[12] Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2018 , 2017 .
[13] P. Lapuerta,et al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes , 2017, The New England journal of medicine.
[14] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[15] B. Zinman,et al. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk , 2017, Stroke.
[16] Björn Eliasson,et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.
[17] Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019 , 2018 .
[18] S. Verma,et al. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. , 2016, Clinical therapeutics.
[19] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[20] M. Monami,et al. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials , 2016, Acta Diabetologica.
[21] John M Lachin,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[22] M. Desai,et al. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus , 2016, Current medical research and opinion.
[23] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.
[24] A. Hoes,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.
[25] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[26] Deepak L. Bhatt,et al. Impact of Diabetes on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years from the REACH Registry , 2015 .
[27] D. Devineni,et al. Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor , 2015, Clinical Pharmacokinetics.
[28] Kristian Thorlund,et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.
[29] F. Pattou,et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.
[30] P. Shekelle,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.
[31] P. Shekelle,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.
[32] A. Scheen. Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor , 2014, Clinical Pharmacokinetics.
[33] P. Nyirjesy,et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies , 2014, Current medical research and opinion.
[34] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[35] A. Scheen. Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus , 2014, Drugs.
[36] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[37] Katja Jasinskaja,et al. Elaboration and Explanation ⋆ , 2011 .
[38] Wolfgang Viechtbauer,et al. Conducting Meta-Analyses in R with the metafor Package , 2010 .
[39] G. Boysen,et al. European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.
[40] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[41] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[42] A. Hoes,et al. [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.
[43] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[44] J. Hartung,et al. A refined method for the meta‐analysis of controlled clinical trials with binary outcome , 2001, Statistics in medicine.